Determination of dose enhancement caused by AuNPs with Xoft® Axxent® Electronic (eBx TM) and conventional brachytherapy: in vitro study

Shahhoseini, E, Ramachandran, P, Patterson, W and Geso, M 2018, 'Determination of dose enhancement caused by AuNPs with Xoft® Axxent® Electronic (eBx TM) and conventional brachytherapy: in vitro study', International Journal of Nanomedicine, vol. 13, pp. 5733-5741.


Document type: Journal Article
Collection: Journal Articles

Title Determination of dose enhancement caused by AuNPs with Xoft® Axxent® Electronic (eBx TM) and conventional brachytherapy: in vitro study
Author(s) Shahhoseini, E
Ramachandran, P
Patterson, W
Geso, M
Year 2018
Journal name International Journal of Nanomedicine
Volume number 13
Start page 5733
End page 5741
Total pages 9
Publisher Dove Medical Press Ltd.
Abstract Purpose: The purpose of this study was to determine dose enhancement (DE) and the possible clinical benefits associated with the inclusion of gold nanoparticles (AuNPs) in cancer cells irradiated by either an Ir-192 brachytherapy source or a Xoft (R) Axxent (R) Electronic (eBx (TM)) Brachytherapy. Patients and methods: Brachytherapy DE caused by AuNPs is investigated using two methods, namely Ir-192 and eBx (TM) Brachytherapy. The second method, which was recently introduced clinically, operates at similar to 50 kV, which is also the optimal beam energy for DE. In this in vitro study, two cancer cell lines, lung (A549) and prostate (DU145), were used. Cells were incubated with 1 mM (2% w/w) concentration of AuNPs of similar to 15 nm in size. The control groups were exposed to a range of doses from 0 (control) to 6 Gy, with eBx (TM) and Ir-192 sources separately. A clonogenic assay was conducted to determine cell survival curves. Results: High dose enhancement factor (DEF) values were achieved in treated groups with low concentration of AuNPs with the 50 kV energy associated with the eBx (TM). The DE levels in eBx (TM) for Du145 and A549 cells were found to be 2.90 and 2.06, respectively. The results showed DEFs measured for the same cell lines using Ir-192 brachytherapy to be 1.67 and 1.54 for Du145 and A549 cancer cells, respectively. This clearly indicates that much higher DE values are obtained in the case of eBx (TM) X-ray brachytherapy compared to Ir-192 gamma brachytherapy. Conclusion: The higher DE values obtained with eBx (TM) compared to Ir-192 brachytherapy can be attributed to the lower average energy of the former and being closer to the optimal energy for DE. This could potentially be utilized by medical practitioners and clinicians to achieve the same tumor control with a significantly lower dose from the eBx (TM) compared to the Ir-192 brachytherapy treatment, thus bringing huge benefits to the brachytherapy-treated patients.
Subject Medical Physics
Keyword(s) gold nanoparticles
Xoft
Electron brachytherapy
DOI - identifier 10.2147/IJN.S174624
Copyright notice © 2018 Shahhoseini et al.
ISSN 1176-9114
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Altmetric details:
Access Statistics: 5 Abstract Views  -  Detailed Statistics
Created: Thu, 27 Jun 2019, 10:20:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us